There has been growing discussion regarding the most effective way to image neuroendocrine tumors, including pheos and paras, which culminated with an announcement on June 1st that the United States Food and Drug Administration (FDA) has approved the use of Netspot. Netspot is a kit designed to deliver a single dose of radioactive diagnostic agent Ga-68 DOTA-TATE to patients via injection during positron emission tomography (PET) imaging.
Dr. Jorge Carasquillo spoke to attendees at the Pheochromocytoma and Paraganglioma 2015 International Conference about imaging techniques in his presentation on Modern Imaging. Dr. Carasquillo’s illuminating talk presented ample evidence for the superiority of PET imaging used in conjunction with Ga-68 DOTA-compounds when looking for pheochromocytomas and paragangliomas.
We’d like to append a special note to radiologists and patients reading this: Because of the great value of these scans to patients, we are currently in the process of compiling a global list of facilities which offer Ga-68 DOTA PET imaging. We are very interested in hearing from providers who offer them, and also from patients who have received them. Please contact us with the details, and be sure to leave information on how we can reach you for more information.
This video is hosted by the Pheo Para Troopers, who also organized the conference from which it was taken. The Pheo Para Troopers is the largest patient-centered organization dealing exclusively with pheochromocytoma and paraganglioma, and is a wonderful resource for both patients and healthcare professionals.
The videos for the conference are exclusively supported by the Firefox browser.